Search

Your search keyword '"F. Pouyol"' showing total 6 results
Start Over Author "F. Pouyol" Topic multiple myeloma
6 results on '"F. Pouyol"'

1. Non-secretory multiple myeloma with multinucleated giant plasma cells.

Author

Ghevaert C, Fournier M, Bernardi F, Geneviève F, Pouyol F, and Zandecki M

Subjects
Aged, Humans, Male, Multiple Myeloma pathology, Plasma Cells pathology
Abstract

We report a case of non-secretory multiple myeloma with unusual cytological features. The plasma cells were multinucleated and contained up to forty nuclei. All nuclei had regular outlines without multilobulated and convoluted slopes. DNA content measurement demonstrated that all nuclei of uni- and multinucleated cells were diploid. All plasma cells contained cytoplasmic alpha chain but light chains and their corresponding transcripts were absent. There is no clear explanation concerning multinuclearity. In addition, hypotheses regarding non-secretion of immunoglobulin in non-secretory multiple myeloma and in other B-cell neoplasias are discussed.

Published
1997
Full Text
View/download PDF

2. Treatment of multiple myeloma with etidronate: results of a multicentre double-blind study. Groupe d'Etudes et de Recherches sur le Myélome (GERM).

Author

Daragon A, Humez C, Michot C, Le Loet X, Grosbois B, Pouyol F, Euller-Ziegler L, Azais I, Bernard JF, and Menard JF

Subjects
Aged, Biopsy, Bone and Bones diagnostic imaging, Bone and Bones drug effects, Chi-Square Distribution, Double-Blind Method, Etidronic Acid adverse effects, Female, France epidemiology, Humans, Ilium pathology, Male, Middle Aged, Multiple Myeloma diagnostic imaging, Multiple Myeloma epidemiology, Multiple Myeloma pathology, Prospective Studies, Radiography, Etidronic Acid therapeutic use, Multiple Myeloma drug therapy
Abstract

Objectives: Because osteoclastic bone resorption is stimulated in multiple myeloma, we evaluated the efficacy of etidronate in this disease, in a multicentre controlled study., Methods: Ninety-four previously untreated patients with stage II or III multiple myeloma received, in addition to the same chemotherapy, 10 mg/kg/day etidronate per os (n = 49) or placebo (n = 45) for 4 months. The evaluation was clinical (pain, Karnofsky, survival), biological and radiological. Forty-one patients had iliac bone biopsy before the treatment and 34 patients also at the end of the study. Histologic bone parameters were compared with 49 normal controls., Results: No statistical difference was found between etidronate and placebo treated patients for clinical, biological and radiological parameters. Compared with controls, pretreatment biopsies showed markedly increased bone resorption and decreased trabecular bone volume. Bone resorption decreased significantly in patients with etidronate compared with those with placebo (p < 0.05)., Conclusion: Though we found no clinical, biological and radiological difference with placebo, etidronate inhibited the increased bone resorption in multiple myeloma.

Published
1993

3. Treatment of multiple myeloma with etidronate: results of a multicentre double-blind study. Groupe d'Etudes et de Recherches sur le Myélome (GERM)

Author

A, Daragon, C, Humez, C, Michot, X, Le Loet, B, Grosbois, F, Pouyol, L, Euller-Ziegler, I, Azais, J F, Bernard, and J F, Menard

Subjects
Male, Chi-Square Distribution, Biopsy, Etidronic Acid, Middle Aged, Bone and Bones, Ilium, Radiography, Double-Blind Method, Humans, Female, France, Prospective Studies, Multiple Myeloma, Aged
Abstract

Because osteoclastic bone resorption is stimulated in multiple myeloma, we evaluated the efficacy of etidronate in this disease, in a multicentre controlled study.Ninety-four previously untreated patients with stage II or III multiple myeloma received, in addition to the same chemotherapy, 10 mg/kg/day etidronate per os (n = 49) or placebo (n = 45) for 4 months. The evaluation was clinical (pain, Karnofsky, survival), biological and radiological. Forty-one patients had iliac bone biopsy before the treatment and 34 patients also at the end of the study. Histologic bone parameters were compared with 49 normal controls.No statistical difference was found between etidronate and placebo treated patients for clinical, biological and radiological parameters. Compared with controls, pretreatment biopsies showed markedly increased bone resorption and decreased trabecular bone volume. Bone resorption decreased significantly in patients with etidronate compared with those with placebo (p0.05).Though we found no clinical, biological and radiological difference with placebo, etidronate inhibited the increased bone resorption in multiple myeloma.

Published
1993

4. Traitement du myélome multiple par un biphosphonate: résultats d'une étude contrôlée de l'Etidronate contre Placebo

Author

F. Pouyol, Ch. Michot, Alain Daragon, J.F. Bernard, X. Le Loët, Mathieu Monconduit, Ch. Humez, Bernard Grosbois, Isabelle Azais, and Liana Euller-Ziegler

Subjects
medicine.medical_specialty, business.industry, Gastroenterology, Urology, medicine.disease, Placebo, Bone resorption, Surgery, Internal Medicine, Medicine, business, Bone biopsy, Multiple myeloma, After treatment
Abstract

In a multicentric controlled study, 49 patients with multiple myeloma (MM) received etidronate (10 mg/kg/j), and 45 received placebo, for 4 months. No difference was found for clinical, biological and radiogical parameters. 41 MM had bone biopsy before and after treatment: bone resorption parameters decreased significantly with etidronate (p

Published
1992
Full Text
View/download PDF

5. Efficacy of etidronate (EHDP) on bone in multiple myeloma. Results of a multicentric double blind study

Author

J.F. Bernard, Jean-François Ménard, Isabelle Azais, Mathieu Monconduit, Liana Euller-Ziegler, F. Pouyol, C. Humez, Alain Daragon, X. Le Loet, Chantal Michot, and Bernard Grosbois

Subjects
Double blind study, medicine.medical_specialty, Endocrinology, business.industry, Urology, Medicine, Surgery, business, medicine.disease, Biochemistry, Multiple myeloma
Published
1992
Full Text
View/download PDF

6. L'association polyarthrite rhumatoïde/myélome est-elle fortuite ?

Author

R.M. Flipo, Thierry Facon, D. Bontoux, Deshayes P, H. Dorfman, Bernard Delcambre, X. Le Loet, F. Pouyol, J. Strauss, G. Kaplan, P.-H. Lore, M. F. Kahn, R. Bataille, Duquesnoy B, P. Chicault, J. Crouzet, J. L. Siame, X. Deprez, J. Arlaud, and S. Hary

Subjects
medicine.medical_specialty, business.industry, Gastroenterology, Prevalence, medicine.disease, Dermatology, Multicenter study, hemic and lymphatic diseases, Rheumatoid arthritis, Epidemiology, Immunology, Internal Medicine, Medicine, business, Multiple myeloma
Abstract

Some epidemiological and pathogenic data are in favor of a significant association between rheumatoid arthritis and multiple myeloma. In a multicenter study, 19 cases of association of both pathologies are reviewed. On account of the prevalence rate of myeloma and RA, only 19 cases of association of both pathologies are in favor of a coincidental association.

Published
1991
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results